Category:Statins
Vai alla navigazione
Vai alla ricerca
farmaci che inibiscono la sintesi del colesterolo endogeno agendo sull'enzima idrossimetilglutaril-CoA reduttasi | |||||
| Carica un file multimediale | |||||
| Istanza di |
| ||||
|---|---|---|---|---|---|
| Sottoclasse di |
| ||||
| Parte di |
| ||||
| |||||
Sottocategorie
Questa categoria contiene un'unica sottocategoria, indicata di seguito.
H
File nella categoria "Statins"
Questa categoria contiene 42 file, indicati di seguito, su un totale di 42.
-
Advlip.jpg 911 × 615; 51 KB
-
Algorithm for statin-associated myopathy.jpg 810 × 900; 88 KB
-
Biosynthesis-dielsalder.png 1 523 × 1 602; 77 KB
-
Biosynthesis-lovd.png 1 442 × 1 177; 60 KB
-
Cholesterolbiosynthesis.png 1 930 × 2 427; 40 KB
-
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s2.ogv 20 s, 1 344 × 1 024; 15,49 MB
-
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s3.ogv 20 s, 1 344 × 1 024; 12,31 MB
-
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s4.ogv 20 s, 1 344 × 1 024; 10,26 MB
-
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s5.ogv 19 s, 1 344 × 1 024; 18,75 MB
-
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s6.ogv 13 s, 1 344 × 1 024; 10,5 MB
-
-
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s8.ogv 13 s, 1 344 × 1 024; 10,57 MB
-
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s9.ogv 13 s, 1 344 × 1 024; 8,86 MB
-
Estatina final.png 315 × 209; 13 KB
-
Estatina.png 578 × 174; 17 KB
-
Fluvastatina Grupo fluorofenil.jpg 468 × 311; 26 KB
-
HMG-CoA reductase pathway.svg 500 × 911; 16 KB
-
Metabolic pathway of a typical statin.png 4 762 × 4 757; 221 KB
-
-
Ogólny mechanizm plejotropowego działania statyn.png 3 507 × 2 480; 403 KB
-
Schematyczna budowa cząsteczki statyn.png 4 877 × 2 170; 109 KB
-
Statin final.svg 210 × 139; 14 KB
-
Statin mechanism v01.svg 652 × 282; 65 KB
-
Statin pharmacophore 2.png 3 787 × 2 861; 63 KB
-
Statin pharmacophore.png 665 × 614; 7 KB
-
Statin pharmacophore.svg 162 × 142; 10 KB
-
Statin Risks (6941350219).jpg 2 784 × 2 702; 1,08 MB
-
Statin-Test.png 838 × 759; 66 KB
-
Statin-use-cardiovascular-disease-death-rate.png 3 400 × 3 844; 1,4 MB
-
Statin-use-vs-share-of-population-with-high-blood-pressure.png 3 400 × 3 865; 1,37 MB
-
Statin.svg 385 × 116; 17 KB
-
Statinfamily.png 1 144 × 315; 48 KB
-
StatinPathway WP430.png 828 × 743; 62 KB
-
Statins-1.generation v01.svg 988 × 476; 103 KB
-
Statins77.png 516 × 461; 38 KB
-
-
Wpływ fluwastatyny na wskaźniki lipidowe 01.png 1 747 × 1 900; 69 KB
-
Wpływ fluwastatyny na wskaźniki lipidowe 02.png 1 747 × 1 891; 46 KB
-
Wpływ fluwastatyny na wskaźniki lipidowe 03.png 1 751 × 1 900; 78 KB
-
Wpływ prawastatyny na wskaźniki lipidowe 01.png 1 747 × 1 900; 75 KB
-
Wpływ prawastatyny na wskaźniki lipidowe 02.png 1 747 × 1 891; 77 KB
-
Wpływ prawastatyny na wskaźniki lipidowe 03.png 1 755 × 1 900; 82 KB